Omalizumab for previously treated chronic spontaneous urticaria

  • Technology appraisal guidance
  • TA339
  • Published: 
Download guidance (PDF)

6 Review of guidance

6.1 The guidance on this technology will be considered for review 3 years after publication of the guidance. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
May 2015